Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Yearly Archives: 2016

Aegis’ Protek® Excipients Provide A Superior Alternative To Polysorbates In Preventing Protein Aggregation And Unwanted Oxidative Damage And Immunogenicity

SAN DIEGO, CA March 23, 2016 — Biotherapeutics incorporating alkylglucosides rather than polysorbates are likely to achieve substantial commercial benefits and a strong and differentiable market franchise for innovator biotherapeutics and biosimilars. Aggregation-induced neutralizing antibodies and anaphylactic reactions sometimes associated with polysorbates are serious and growing concerns of both the FDA and the European Medicines […]

Aegis Awarded 8th Patent for Fast Acting Migraine Nasal Spray Treatment

SAN DIEGO, CA March 17, 2016/Marketwire — Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,283,280, its eighth patent, third in the US, providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan.  […]